Hemophilia



Bleeding Risk Evaluation in Haemophilia Patients Under Antiplatelet Therapies


Condition:   Hemophilia
Intervention:   Other: Non interventional study
Sponsor:   Nantes University Hospital
Not yet recruiting - verified May 2017


PF-06741086 Multiple Dose Study in Severe Hemophilia


Condition:   Hemophilia A or B
Interventions:   Biological: PF-06741086;   Biological: PF-06741086;   Biological: PF-06741086;   Biological: PF-06741086
Sponsor:   Pfizer
Recruiting - verified May 2017


Long-Term Safety, Tolerability, and Efficacy of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B


Condition:   Hemophilia B
Intervention:  
Sponsor:   Dimension Therapeutics
Recruiting - verified January 2017


Drug Use Investigation of Kovaltry in Hemophilia A Patients


Condition:   Hemophilia A
Intervention:   Drug: Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973)
Sponsor:   Bayer
Recruiting - verified May 2017


National Survey of People With Haemophilia in Portugal


Condition:   Haemophilia
Intervention:  
Sponsors:   University of Minho;   Hospital Sao Joao;   Portuguese hemophilia association and other congenital coagulopathies
Completed - verified May 2017


A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors


Condition:   Hemophilia A
Intervention:   Drug: Emicizumab
Sponsors:   Hoffmann-La Roche;   Chugai Pharmaceutical
Recruiting - verified March 2017


Educational Physiotherapy in Haemophilia


Condition:   Haemophilia
Intervention:   Other: Educational physiotherapy group
Sponsor:   Real Fundación Victoria Eugenia
Completed - verified July 2016


Does the Thrombin Generation Test Performed During the Pharmacokinetic Profile of the Substitutive Factor VIII Bring Benefits to the Personalized Treatment of Pediatric Patients and Adult Hemophilia A Patients Under Prophylaxis ?


Condition:   Hemophilia
Interventions:   Device: Chronometric method;   Device: Chromogenic method;   Device: Thrombin generation test (TGT)
Sponsor:   Brugmann University Hospital
Not yet recruiting - verified June 2016


The Hemophilia Ultrasound Project


Conditions:   Hemophilia A;   Hemophilia B
Interventions:   Other: Ankle and Knee Ultrasound Joint Assessment;   Other: Ankle and Knee Magnetic Resonance Imaging
Sponsors:   University of Miami;   Baxalta US Inc.
Recruiting - verified August 2016


Evaluation of a Simple Pharmacokinetic Tool (myPKFiT™) to Guide Personalized Factor VIII Dosing in Patients With Hemophilia


Condition:   Hemophilia A
Intervention:  
Sponsors:   Victor Blanchette;   St. Paul's Hospital, Vancouver (Providence Health Care);   Montreal Children's Hospital of the MUHC;   Queen's University
Enrolling by invitation - verified November 2016


PK Driven Prophylaxis for Hemophilia A


Condition:   Hemophilia A
Intervention:   Device: MyPKFiT
Sponsors:   Assistance Publique - Hôpitaux de Paris;   Baxter Healthcare Corporation
Active, not recruiting - verified August 2016


Safety and Dose Finding Study of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B


Condition:   Hemophilia B
Interventions:   Genetic: AAVrh10FIX;   Genetic: AAVrh10FIX;   Genetic: AAVrh10FIX;   Genetic: AAVrh10FIX
Sponsor:   Dimension Therapeutics
Active, not recruiting - verified May 2017


Extension at 10 Years of the: "Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A."


Condition:   Hemophilia A
Interventions:   Drug: Recombinant Factor VIII (Kogenate FS, BAY14-2222);   Drug: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Sponsor:   Bayer
Recruiting - verified May 2017


National Study of a Pharmacokinetic-Focused Educational Package for Patients With Severe Haemophilia A


Condition:   Hemophilia A
Intervention:   Behavioral: Educational Package
Sponsor:   Hampshire Hospitals NHS Foundation Trust
Active, not recruiting - verified February 2017


Global Haemostatic Methods Following Administration of Bypassing Agents to Patients With Haemophilia With Inhibitors


Condition:   Hemophilia
Intervention:  
Sponsor:   Karolinska Institutet
Recruiting - verified March 2017


Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B


Condition:   Hemophilia B
Intervention:   Genetic: AAV5-hFIX
Sponsors:   UniQure Biopharma B.V.;   Chiesi Farmaceutici S.p.A.
Active, not recruiting - verified February 2017


Platelet Function in Patients With Hemophilia A


Condition:   Hemophilia A
Intervention:  
Sponsors:   Boston Children’s Hospital;   Baxter Healthcare Corporation
Enrolling by invitation - verified January 2017


Multicentre, Non-controlled, Prospective, Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A


Condition:   Haemophilia A
Intervention:   Biological: Optivate 500IU
Sponsor:   Bio Products Laboratory
Recruiting - verified December 2016


Inhibitor Development in Patients With Hemophilia A Undergoing Surgery


Condition:   Hemophilia A
Intervention:  
Sponsors:   Emory University;   National Institutes of Health (NIH);   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified April 2017


A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A


Condition:   Hemophilia A
Intervention:   Biological: BAY94-9027
Sponsor:   Bayer
Active, not recruiting - verified July 2016


A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A


Condition:   Hemophilia A
Interventions:   Biological: rFVIII (BAY81-8973) on demand;   Biological: rFVIII (BAY81-8973) prophylaxis low-dose;   Biological: rFVIII (BAY81-8973) prophylaxis high-dose
Sponsor:   Bayer
Completed - verified October 2016


Bleeding Symptoms of Carriers of Hemophilia A and B


Condition:   Hemophilia
Intervention:  
Sponsor:   Sahlgrenska University Hospital, Sweden
Completed - verified October 2016


Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients


Condition:   Hemophilia A
Interventions:   Biological: Moroctocog alfa ( AF-CC);   Procedure: Laboratory tests
Sponsor:   Pfizer
Completed - verified December 2016


Phase I/IIa Study of FIXFc in Hemophilia B Patients


Condition:   Hemophilia B
Intervention:   Drug: rFIXFc
Sponsors:   Bioverativ Therapeutics Inc.;   Syntonix Pharmaceuticals, Inc.;   Swedish Orphan Biovitrum
Completed - verified February 2017


Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery


Condition:   Hemophilia A
Interventions:   Drug: Recombinant Protein-Free Factor VIII (rAHF-PFM);   Drug: Recombinant Protein-Free Factor VIII (rAHF-PFM)
Sponsors:   Baxalta US Inc.;   Baxalta Innovations GmbH, now part of Shire
Completed - verified January 2017

Refine Your Search Advanced Search